TX-KAHUNA-WORKFORCE
6.2.2024 10:08:34 CET | Business Wire | Press release
Kahuna Workforce Solutions, the leading provider of skills and competency management software, has formed a strategic partnership with Norwegian operating services provider PXO AS to accelerate workforce competency in Norway’s booming energy sector, which is a significant stabilizer of the world’s oil and gas supply, particularly in meeting European demand.
The two companies, both of which already have established customers in Norway, have identified opportunities to jointly support the region’s growing demand for technically skilled professionals in the energy sector. The partnership specifically aims to improve operations readiness and assurance by combining Kahuna’s dynamic, digitized competency management platform with PXO’s extensive technical and field experience in a variety of operating production facilities offshore and onshore.
“PXO represents everything we look for in a partner as we strive to ensure successful and rapid adoption of competency-based training and development programs,” said Jai Shah, CEO of Kahuna Workforce Solutions. “As a company that works with many of the same customers as PXO, we’ve seen their expertise firsthand. It is clear they are the right partner to help us not only address the current needs of the energy industry but also pioneer innovative solutions that will shape the future of competency readiness and assurance in Norway.”
The collaboration comes at a critical time for the region, as Norway expects to draw nearly $22 billion in investments from oil and gas companies in 2024. The country is also leading the world toward cleaner energy solutions. Kahuna and PXO’s partnership will help Norwegian energy companies navigate this transition in a variety of ways, including streamlining skills validation and aligning operational standards with expanding ESG initiatives and emerging technologies.
“Just as we serve as a bridge between project and operation phases, Kahuna equips enterprises with validated competency data,” said Leif Olav Moe, CEO of PXO. “By uniting our technical and operational expertise with their cutting-edge competency management solutions, we are delivering a unique solution unlike anything the market has yet to provide—signifying our commitment to building a more skilled and competitive workforce to ascertain safer and more efficient operations.”
"At Kahuna, we are empowering organizations throughout the energy value chain by providing validated competency data and unique insights. This enables a deep understanding of workforce capabilities for seamless operational execution, in addition to aligning talent supply with demand and maximizing the return on investment in technical training,” Shah said. “When you combine our capabilities with PXO’s extensive experience in supporting operations with strategic training and competency services, there is no other competency management solution that comes close to building a skilled, safe, compliant, and competitive workforce.”
About Kahuna Workforce Solutions
Kahuna Workforce Solutions is the only skills management software built for operations, learning, and human resources. Kahuna equips enterprise organizations with validated skills data to understand workforce capability, align talent supply and demand, and increase the return on training investment. Across a wide array of industries including healthcare, energy, manufacturing, and aerospace, Kahuna helps organizations build a more skilled, competitive workforce. For more information, visit https://kahunaworkforce.com/.
About PXO
PXO's services are mainly within the petroleum industry with field operating companies as clients, however, the services are also applied within other industry segments, such as shipping, renewable energy and aquaculture.
PXO increases awareness of safety barriers and their functions to improve efficiency and safety in field operations. Exposed to increasingly demanding requirements from authorities, clients, suppliers, and other stakeholders as regards knowledge and experience require systematic and targeted competence development of operations personnel in particular, extending from planning through construction & start-up and into regular operations. PXO ensures that prevailing competence requirements are met and followed up through various measures:
- Systematization of specific competence requirements
- Development of model-based interactive management tools (portal solutions)
- Harmonization of job descriptions and work processes
- Development and execution of training plans through interactive computer based training and practical On the Job Training (OJT) programmes.
PXO is focused on the interaction between people, organization and technology as a means to optimize, integrate and align work processes and technical equipment for robust and safe overall solutions.
For more information, visit https://www.pxo.no/en
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240206626623/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom